CVS/$CVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About CVS

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health adds primary care services to the mix, which could have significant synergies with all existing business lines.

Ticker

$CVS
Sector

Primary listing

NYSE

Employees

259,500

CVS Metrics

BasicAdvanced
$91B
19.98
$3.59
0.59
$2.66
3.71%

What the Analysts think about CVS

Analyst ratings (Buy, Hold, Sell) for CVS stock.

Bulls say / Bears say

CVS increased its 2025 earnings projection to $6.30–$6.40 per share after reporting Q2 adjusted EPS of $1.81, beating analyst expectations of $1.46. This marks the company's third straight quarterly earnings beat and suggests strong financial momentum (Reuters).
CVS’s Aetna insurance unit posted a Q2 2025 medical loss ratio of 89.9%, better than analysts’ estimate of 91.16%, reflecting stronger underwriting control and cost efficiency (Reuters).
Revenue in CVS’s health services segment climbed 10.2% and retail pharmacy sales jumped 12.5% year-over-year in Q2 2025, showing continued strong demand in its PBM, primary care, and pharmacy businesses (Reuters).
CVS plans to shut down 250 physical pharmacy locations in 2025 amid cost reduction strategies, pointing to persistent challenges in its retail division and suggesting possible short-term revenue pressure (Reuters).
Louisiana Attorney General Liz Murrill filed three lawsuits against CVS in June 2025, accusing its PBM unit of unfair, deceptive, and illegal practices. These cases highlight legal and regulatory risks that could lead to costly injunctions or required restitution (Reuters).
A Mercer survey in July 2025 showed 34% of large U.S. employers are considering moving away from traditional PBMs like CVS Caremark due to concerns about transparency and pricing, threatening Caremark’s market positioning (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

CVS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CVS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CVS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs